Reading this on a mobile device? Try our optimized mobile version here:

March 31, 2009
Enter the Be the Buzz of BIO Contest to get great exposure for your company. Be chosen to receive a Full Convention Access Registration plus partnering and a BIO Business Forum Company Presentation slot. Online voting on finalists begins April 1.

The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at

  Today's Top Story 
 FREE REPORT – The Future of Biotech!
This comprehensive report into the future of our industry provides expert advice from some of the best minds in biotechnology. You'll see where our industry is headed – and what you can do to prepare yourself for that future. Published by BioWorld Today. Click here now to download your FREE report.

  Health Care in Transition 
  • HHS report calls for overhaul of health care system
    Soaring costs and a broken delivery system highlight the need to overhaul health care this year, according to an HHS report released online. U.S. spending for medical care reached $2.2 trillion in 2007, and such expenses are expected to account for 25% of gross domestic product by 2025, the report noted. Yahoo!/Reuters (3/30) LinkedInFacebookTwitterEmail this Story
  • Other News
  Health Care & Policy 
  • Bone marrow cells improve cardiac function in heart attack patients
    Patients who received higher doses of AMR-001 -- bone marrow stem cells that had started to transform into endothelial cells -- after suffering a heart attack showed better blood circulation in the heart than those who got lower doses of cells or took drugs alone, according to a study by biotech firm Amorcyte. The company plans to conduct a larger clinical trial of AMR-001, said Dr. Andrew Pecora, chairman of the Amorcyte board. Yahoo!/Reuters (3/30) LinkedInFacebookTwitterEmail this Story
 Free Whitepaper: Enterprise Sales Contract Management for Life Sciences
Leading life sciences companies are recognizing the need for synchronized, enterprise-wide pricing and sales contract management processes. Learn more about how an integrated solution can provide the transparency needed to satisfy auditors, balance pricing with go-to-market strategies, and support sales and finance teams –including accurately predicting margins.

  Company & Financial News 
  • Novartis' kidney cancer drug everolimus wins FDA approval
    The FDA cleared Novartis AG's kidney cancer medicine everolimus for patients who fail to respond to other treatments. The approval was based on clinical-trial results showing that everolimus prevented tumor growth for five months of therapy. Novartis plans to market the drug under the brand name Afinitor. USA TODAY (3/30) LinkedInFacebookTwitterEmail this Story
  • Arena obesity drug yields modest results in Phase III trial
    Arena Pharmaceuticals reported that its weight-loss pill lorcaserin met FDA requirements in a Phase III trial, in which 47.5% of patients who took the drug for a year showed a weight reduction of at least 5%, compared with 20.3% of patients who received placebo. Arena said it intends to wait for the conclusion of another late-stage study in September before seeking FDA approval for the treatment. (3/30) LinkedInFacebookTwitterEmail this Story
  • Other News
  Global Developments 
  • Survey: U.K. biotech companies struggle to raise funds
    Nearly three-quarters of 295 U.K. life sciences companies surveyed by the BioIndustry Association said they faced difficulties securing funding during the past year. In its letter to Chancellor of the Exchequer Alistair Darling, the group urged the government to initiate programs to support the industry, such as providing research and development tax credits and greater government funding for small firms with experimental drugs. Financial Times (free content) (3/29) LinkedInFacebookTwitterEmail this Story
  • Reliance Life Sciences to unveil 4 follow-on biologics in 2010
    Reliance Life Sciences is conducting clinical trials of four follow-on biologics, which are aimed at oncology and cardiology markets, and plans to introduce the drugs next year. The Indian company, which unveiled three biosimilars in 2008, plans to market its treatments in the U.S. and Europe once a regulatory pathway for such products transpires, a company official said. Business Standard (India) (3/29) LinkedInFacebookTwitterEmail this Story
  Featured Content 

  Food & Agriculture 
  • 2 groups to work on improving crops in developing countries
    The Bill & Melinda Gates Foundation and the National Science Foundation have agreed to invest $48 million over five years in an initiative aimed at finding ways to boost agricultural productivity in Africa and developing countries, as well as make crops resistant to factors including disease and drought. Known as BREAD: Basic Research to Enable Agricultural Development, the project could include studies on biotech plants, an NSF official said. The Seattle Times (3/30), American City Business Journals/Seattle (3/30) LinkedInFacebookTwitterEmail this Story
  News from BIO 
  • BIO introduces the One-on-One Services
    BIO introduces its One-on-One Services, three networking tools to enhance your meetings productivity. BIO One-on-One Partnering is an interactive environment that allows you to intelligently search, contact and schedule private meetings with potential partners and investors at BIO meetings. The BIO One-on-One Forum provides ongoing access to news feeds and financial data about all the presenting companies -- before, during and after BIO conferences. BIO One-on-One Meeting Room Banks allows member companies to book rooms for private 30-minute meetings at major medical and industry conferences at no cost. LinkedInFacebookTwitterEmail this Story
Learn more about BIO ->Conferences  |  Join BIO  |  Media  |  Issues  |  Industry

You can do anything -- but not everything."
--David Allen,
productivity consultant

LinkedInFacebookTwitterEmail this Story

Subscriber Tools
Print friendly format | Web version | Search past news | Archive | Privacy policy

Account Executive:  Meryl Harold (202) 407-7828
A powerful website for SmartBrief readers including:
 Recent BIO SmartBrief Issues:   Lead Editor:  Ashley McMaster
Mailing Address:
SmartBrief, Inc.®, 1100 H ST NW, Suite 1000, Washington, DC 20005
© 1999-2011 SmartBrief, Inc.® Legal Information